Aditxt (NASDAQ:ADTX) Price Target Increased to $61.00 by Analysts at HC Wainwright

Aditxt (NASDAQ:ADTX) had its price target lifted by research analysts at HC Wainwright to $61.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 170.87% from the company’s previous close. HC Wainwright also issued estimates for Aditxt’s Q3 2023 earnings at ($7.98) EPS, Q4 2023 earnings at ($4.47) EPS, Q1 2024 earnings at ($3.33) EPS, Q2 2024 earnings at ($2.69) EPS, Q3 2024 earnings at ($2.74) EPS, Q4 2024 earnings at ($2.64) EPS and FY2024 earnings at ($11.29) EPS.

Aditxt Stock Performance

Shares of ADTX traded down $2.98 during trading hours on Wednesday, hitting $22.52. 99,403 shares of the company were exchanged, compared to its average volume of 70,761. The firm’s fifty day moving average is $31.43 and its 200 day moving average is $30.56. Aditxt has a fifty-two week low of $7.34 and a fifty-two week high of $1,139.60.

Aditxt (NASDAQ:ADTX) last announced its quarterly earnings data on Monday, August 14th. The company reported ($36.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($115.60) by $78.80. Aditxt had a negative net margin of 2,891.14% and a negative return on equity of 777.58%. The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.36 million. Sell-side analysts expect that Aditxt will post -235.2 EPS for the current fiscal year.

Insider Buying and Selling at Aditxt

In other news, major shareholder Paribas Securities Corp Bnp sold 20,800 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $33.23, for a total value of $691,184.00. Following the completion of the transaction, the insider now directly owns 22,342 shares in the company, valued at approximately $742,424.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.23% of the company’s stock.

Institutional Trading of Aditxt

An institutional investor recently bought a new position in Aditxt stock. Bank of New York Mellon Corp acquired a new position in Aditxt, Inc. (NASDAQ:ADTX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 34,968 shares of the company’s stock, valued at approximately $119,000. Bank of New York Mellon Corp owned approximately 2.99% of Aditxt at the end of the most recent quarter.

About Aditxt

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.